Datapoint: Urovant Prepares for March Gemtesa Launch

Urovant Sciences is gearing up for a March launch of its first FDA-approved drug, Gemtesa, a beta-3 adrenergic receptor agonist which treats overactive bladder (OAB). The OAB market basket is rather crowded, and Gemtesa will have to face off against Astellas Pharma’s leading Myrbetriq, which currently holds preferred status without utilization management restrictions for 45% of all covered lives under the pharmacy benefit.

SOURCE: MMIT Analytics, as of 1/25/21

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 5

Datapoint: North Carolina Delays Launch of New Medicaid MCOs

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 4

Datapoint: FDA Approves Avastin Biosimilar

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 3

Datapoint: AstraZeneca, Merck Pull Lynparza in Ovarian Cancer

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today